thalidomide has been researched along with MODS in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma." | 7.76 | Myocarditis during lenalidomide therapy. ( Ahmadi, T; Carver, JR; Chong, EA; Nasta, S; Schuster, SJ; Stonecypher, M; Wheeler, JE, 2010) |
| "To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma." | 3.76 | Myocarditis during lenalidomide therapy. ( Ahmadi, T; Carver, JR; Chong, EA; Nasta, S; Schuster, SJ; Stonecypher, M; Wheeler, JE, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weed, J | 1 |
| Ko, C | 1 |
| Stahl, M | 1 |
| Much, M | 1 |
| Witt, D | 1 |
| Zeidan, AM | 1 |
| Leventhal, J | 1 |
| Farmer, AD | 1 |
| Zanetto, U | 1 |
| Lewis, MJ | 1 |
| Carver, JR | 1 |
| Nasta, S | 1 |
| Chong, EA | 1 |
| Stonecypher, M | 1 |
| Wheeler, JE | 1 |
| Ahmadi, T | 1 |
| Schuster, SJ | 1 |
| Lee, CK | 1 |
| Barlogie, B | 1 |
| Zangari, M | 1 |
| Fassas, A | 1 |
| Anaissie, E | 1 |
| Morris, C | 1 |
| Van Rhee, F | 1 |
| Cottler-Fox, M | 1 |
| Thertulien, R | 1 |
| Muwalla, F | 1 |
| Mazher, S | 1 |
| Badros, A | 1 |
| Tricot, G | 1 |
| Enomoto, N | 1 |
| Takei, Y | 1 |
| Hirose, M | 1 |
| Kitamura, T | 1 |
| Ikejima, K | 1 |
| Sato, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
5 other studies available for thalidomide and MODS
| Article | Year |
|---|---|
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.
Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalid | 2017 |
Explosive proctitis: potential treatments and pitfalls in the treatment of chronic radiation proctitis.
Topics: Aged; Argon; Fatal Outcome; Humans; Laser Coagulation; Male; Multiple Organ Failure; Proctitis; Radi | 2008 |
Myocarditis during lenalidomide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Autopsy; Dexamethasone; Female; Humans; Lenalidomide; Lymp | 2010 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Protective effect of thalidomide on endotoxin-induced liver injury.
Topics: Animals; Calcium; Disease Progression; Escherichia coli; Immunosuppressive Agents; Kupffer Cells; Li | 2003 |